Document:

Exhibit 10.1

     

    CONSOLIDATION
      AND REORGANIZATION AGREEMENT

     

    PARTY
      A:
      YANGLING DAIYING BIOTECH & PHARMACEUTICAL GROUP CO., LTD.

     

    Registration
      Place: No. 10 Taicheng South Rd., Yangling Hi-tech Demonstration Zone,
      Shaanxi

     

    PARTY
      B:
      AIBIN CHEN

     

    Number
      of
      ID Card: 430321195801030012

     

    Home
      Address: Yingbin West Rd., Yu Hu District, Xiang Tan City

     

    PARTY
      C:
      ZHUOBIN LI

     

    Number
      of
      ID Card: 430721197702180192

     

    Home
      Address: Chanling Rd, Group 1, Cheng Guan Town, An Xiang County, Hunan
      Province;

     

    Whereas:
      

     

    Party
      A,
      Party B and Party C are shareholders of Hunan Hua Yang Pharmaceutical Co.,
      Ltd.,
      Party A holds 51% of the total shares, Party B and C hold 49% of total shares
      together through Hong Kong Hua Tai Agent Co., Ltd, (including 17% of shares
      holding by Party B and 32% of shares holding by Party C).

     

    Whereas,
      

     

    Party
      A,
      Party B and Zhongyu Lu are shareholders of Hunan Ze An Pharmaceutical Co.,
      Ltd.,
      Party A holds 65% of total shares, Party B holds 20% of total shares and Zhongyu
      Lu holds 15% of total share. On Dec. 5, 2005, Zhongyu Lu sales his 15% of shares
      to Party B and Party B owes 1.2 million RMB to Zhongyu Lu to obtain these
      shares. Zhongyu Lu is no longer shareholder of Hunan Ze An Pharmaceutical Co.,
      Ltd. 

     

    Whereas:
      

     

    Party
      B
      proposed and Party A agreed to pay Zhongyu Lu and Party B agrees to transfer
      this 15% of shares from Zhongyu to Party A. Party A will pay Zhongyu Lu two
      year
      later started from the date of execution of this agreement. 

     

    
      
         

      

      
        -1-

        
          

        

      

      
         

      

    

    In
      order
      to optimize the capital and resources and cut down operation cost and management
      cost, with the agreement of shareholders of the two companies, the Parties
      will
      reorganize Hunan Hua Yang Pharmaceutical Co., Ltd. and Hunan Ze An
      Pharmaceutical Co., Ltd. The three parties reached the following terms about
      the
      consolidation: 

     

    	1.  	
            SUPPORTING
              FINANCIALS FOR CONSOLIDATIONS: 

          

     

    The
      terms
      of this consolidation is based on the Balance Sheet ended on December 31, 2005
      of Hunan Hua Yang Pharmaceutical Co., Ltd. and Balance Sheet ended on December
      31, 2005 of Hunan Ze An Pharmaceutical Co., Ltd..

     

    	2.  	
            BENEFICIAL
              OWNERSHIP

          

     

    Base
      on
      previous ownership of this two companies and the financials ended on December
      31
      of 2005, both of the parties agrees the registered capital for the company
      after
      consolidation, Hunan Hua Yang Pharmaceutical Co., Ltd., is 38,670,000 RMB,
      among
      this, Yangling Daiying Biotech & Pharmaceutical Co., Ltd. controls capital
      of 26,043,700 RMB which equals to 67.3486% of total shares of the consolidated
      company; Shareholder, Aibin Chen, controls capital of 7,227,900 RMB which equals
      to 18.6912% of total shares of the consolidated company; Shareholder, Zuobin
      Li,
      controls capital of 5,398,400 RMB which equals to 13.9602% of total shares
      of
      the consolidated company. 

     

    	3.  	
            THE
              COMPANY AFTER THE CONSOLICATION: 

          

     

    Name
      of
      the new company: Hunan Hua Yang Pharmaceutical Co., Ltd.;

     

    English
      Name: Hunan Hua Yang Pharmaceutical Co., Ltd.;

     

    Registration
      Place: An Xiang Industrial Park, Hu Nan Province

     

    	4.  	
            CAPITAL,
              BENEFICIAL OWNERSHIP AND DEBT BEFORE THE
              CONSOLIDATION

          

     

    Both
      parties agree all of the existing capital, beneficial ownership and debt of
      Hunan Ze An Pharmaceutical Co., Ltd. will be taken over by Hunan Hua Yang
      Pharmaceutical Company.

     

    	5.  	
            MANAGEMENT
              STRUCTURE OF THE CONSOLIDATED COMPANY: 

          

     

    The
      new
      company will set up the Board of Directors, including five directors; the
      Chairman will be nominated by Party A. It will also set up Governance Committee
      with three governance officers. Chief Executive Officers and financial officers
      will be appointed by the Board of Directors. The company will owns independent
      accounting department. 

     

    
      
         

      

      
        -2-

        
          

        

      

      
         

      

    

    	6.  	
            Started
              from the executive date of the agreement, Party A and Party B shall
              co-operate with each other, and assign somebody to do the registration
              for
              Business, Land, Real Estate, Tax, Production Certificates of Medicines,
              Trademark and other registration process with State Food and Drug
              Administration, Intellectual Property Bureau, and any other necessary
              legal processes for consolidation. 

          

     

    	7.  	
            Both
              parties should try to resolve disputes through negotiation after execution
              of the agreement. If the dispute could not be resolved, both parties
              have
              the right to go through the legal process.

          

     

    	8.  	
            Any
              material matters not included in this agreement can be negotiated between
              two parties. 

          

     

    	9.  	
            The
              Agreement is executed in six of counterparts, each party hold two copies
              and the other two copies were back up at the related
              authorities.

          

     

    

     

    Party
      A:
      Yangling Daiying Biotech & Pharmaceutical Group Co., Ltd.

     

    Legal
      Representative: 

     

    Signature:
      

     

    

     

    Party
      B:
      Aibin Chen

     

    Signature:
      

     

    Party
      C:
      Zhuobin Li

     

    Signature:
      

     

    Date:
      December 18, 2006

    
      
         

      

      
        -3-Prepared and Filed by St Ives Financial

Exhibit 4.1

 

	

FORM OF SUBSCRIPTION AGREEMENT
  
 

The undersigned subscriber or subscribers (the “Investor” and, after purchase of Shares and Warrants as herein defined, the Investor is referred to as a “Stockholder”), intending to be legally bound, hereby irrevocably subscribes (or subscribe) for and agrees to purchase the number of Investment Units (defined below) for the aggregate purchase price set forth in Section 22 of this Subscription Agreement. The Investor agrees to purchase the number of Investment Units (defined below) as provided herein, and to become a Stockholder of BEIJING MED-PHARM CORPORATION, a Delaware corporation (the “Company”), on the terms and conditions
described herein and in the Company’s Confidential Private Placement Memorandum dated December 1, 2006, as amended and supplemented by the First Supplement to Confidential Memorandum dated December 14, 2006, and all exhibits, amendments and supplements thereto (including any further supplements and amendments thereto) (collectively, the “Memorandum”). A copy of the Memorandum, as amended or supplemented through the date hereof, has been received, carefully read and understood by the Investor. All capitalized terms used but not defined herein have the same meanings as contained in the Memorandum.

	

1.
 	

Purchase and Closing.
 

	

 
 	

(a)
 	

The Company has authorized the sale and issuance of up to:
 

	

 
 	

(i)
 	

3,333,333 shares (the “Shares”) of common stock of the Company, $.001 par value per share (the “Common Stock”), and
 

	

 
 	

(ii)
 	

warrants (the “Warrants”) to purchase up to 1,116,666 shares of Common Stock at an exercise price of $5.625 per share (the “Warrant Shares”), and
 

to certain investors in a private placement as described in the Memorandum (the “Offering”). 

	

 
 	

(b)
 	

The Common Stock and the Warrants are being offered and sold only in investment units comprised of 22,222 Shares and a Warrant to purchase 4,444 Shares (an “Investment Unit”) at a purchase price of $100,000 per Investment Unit. The minimum subscription amount is one (1) Investment Unit for a minimum aggregate subscription price of $100,000. The minimum subscription amount may be waived in the discretion of the Company and the Placement Agent with respect to any particular Investor.
 

	

 
 	

(c)
 	

The Company may enter into the same form of Subscription Agreement with other investors (the “Other Investors”) and expects to complete sales of Shares and Warrants to such Other Investors. (The Investor and the Other Investors are hereinafter sometimes collectively referred to as the “Investors,” and the Subscription Agreement executed by the Other Investors are hereinafter sometimes collectively referred to as the “Agreements.”)
 

	

 
 	

(d)
 	

The Company may accept subscriptions from Investors in one or more closings at any time after the Company has received Agreements for the Minimum Offering and prior to December 29, 2006.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-1
 

	

 
 	

(e)
 	

The Investor agrees that the Placement Agent and its Affiliates may purchase and resell any number of Shares and Warrants for their own account on such terms as the Placement Agent shall determine. As used herein, the term “Affiliate” means, as to any named person or entity: (i) any such person or entity, or with respect to any natural person, a member of his or her immediate family (i.e. spouse, siblings, children, and parents); (ii) the legal representative, successor or assignee of, or any general partner, or their respective officers and directors for the benefit of, any such person or entity (or with respect to any natural person, member of his or her immediate family); (iii) any entity of which a majority of the voting equity ownership is owned by any one or
more of the persons or entities referred to in the preceding clauses (i) and (ii); (iv) any officer, director, general partner, employee, stockholder holding ten percent (10%) or more or partner of any person or entity referred to in the preceding clauses (i), (ii) and (iii); and (v) any person or entity directly or indirectly controlling, or under direct or indirect common control with, any person or entity referred to in any of the preceding clauses.
 

	

 
 	

(f)
 	

The Company’s obligation to issue and deliver the Shares and Warrant to the Investor shall be subject to the following conditions, any one or more of which may be waived by the Company: (i) receipt by the Company of a wire transfer of funds in the full amount of the purchase price for the Shares and Warrant being purchased hereunder, (ii) completion of the purchases and sales under the Agreements with the Other Investors, and (iii) the accuracy of the representations and warranties made by the Investors and the fulfillment of those undertakings of the Investors to be fulfilled prior to the Closing.
 

	

 
 	

(g)
 	

The Investor shall deliver to the Company the consideration required to purchase the number of Investment Units subscribed for in this Subscription Agreement (the “Purchase Price”) by delivery of immediately available funds in the amount of the aggregate purchase price set forth in Paragraph 22 of the Subscription Agreement, by wire transfer to the following account: Sovereign Bank 75 State St., Boston MA 02109, ABA # 011075150, Account # 62100181718, Account Name: Beijing Med-Pharm Corp Escrow Account, Attn: Greg Dennison.
 

	

 
 	

(h)
 	

The Investor also shall deliver to the Company the following subscription documents completed and signed:
 

	

 
 	

(i)
 	

one (1) copy of this Subscription Agreement;
 

	

 
 	

(ii)
 	

if the Investor is relying on the advice of a Purchaser Representative, a Purchaser Representative Letter and Questionnaire (in the form to be furnished by the Company upon request by the Investor); and
 

	

 
 	

(iii)
 	

any other documentation reasonably requested by the Company or the Placement Agent.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-2
 

	

        2.

      	

        Receipt
          and Review of Memorandum. The Investor acknowledges that he or she
          has been furnished and has carefully read and understands the Memorandum.
          The Investor further acknowledges that he or she is aware that: 

      

	

 
 	

(a)
 	

there are substantial risks incident to investing in the Shares and Warrants including, but not limited to, those risks summarized under the caption “RISK FACTORS” in the Memorandum;
 

	

 
 	

(b)
 	

no federal or state agency has passed upon the Shares and Warrants or made any finding or determination concerning the merits or fairness of investing in the Shares and Warrants; and
 

	

 
 	

(c)
 	

the offering and sale of the Shares and Warrants is intended to be exempt from registration under (i) Sections 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D of the Securities Act and (ii) the securities laws of certain states.
 

	

3.
 	

Independent Advice. The Investor acknowledges that he or she has reviewed the risks and merits of an investment in the Shares and Warrants with tax, legal and investment counsel and with a Purchaser Representative to the extent deemed advisable by the Investor.
 

	

        4.

      	

Representations of the Investor. The Investor acknowledges, represents and warrants to the Company as follows:
 

	

 
 	

(a)
 	

THE INVESTOR UNDERSTANDS THAT THE REPRESENTATIONS, WARRANTIES, COVENANTS AND AGREEMENTS CONTAINED IN THIS SUBSCRIPTION AGREEMENT ARE MADE AS AN INDUCEMENT TO THE COMPANY TO ACCEPT THE INVESTOR AS A STOCKHOLDER AND TO SELL TO THE INVESTOR THE INVESTMENT UNITS, AND WILL BE RELIED UPON BY THE COMPANY, THE PLACEMENT AGENT AND THEIR RESPECTIVE AFFILIATES AS THE BASIS FOR CLAIMING EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF FEDERAL AND STATE SECURITIES LAWS FOR THE SALE OF INVESTMENT UNITS.
 

	

 
 	

(b)
 	

If the Investor is an individual, he or she: (i) is at least twenty-one (21) years of age, and (ii) is a bona fide resident and domiciliary (not a temporary or transient resident) of the state set forth as his other legal residence below his or her signature on the signature page hereof and has no present intention of becoming a resident of any other state or jurisdiction.
 

	

 
 	

(c)
 	

If the Investor is an entity, the Investor’s principal place of business, which constitutes the jurisdiction in which the Investor made its investment decision to purchase the securities being subscribed for hereunder, below the Investor’s signature line on the signature page hereof
 

	

 
 	

(d)
 	

The Investor is not in the class of persons to which sales of the Shares and Warrants would be prohibited under Rule 2110 of the NASD Conduct Rules and the corresponding interpretative material, IM-2110-1.
 

	

 
 	

(e)
 	

Any information that the Investor has furnished to the Company or the Placement Agent with respect to his or her financial position and business experience, and in any financial statements provided by the Investor to the Company or the Placement Agent, is correct and complete as of the date of this Subscription Agreement, and, further, the Investor will immediately furnish revised or corrected information to the Company or the Placement Agent should there be any material change in such information prior to the Investor’s acquisition of Shares and Warrants.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-3
 

	

 
 	

(f)
 	

The Investor understands that no federal or state agency has passed upon the accuracy of the Memorandum nor made any finding or determination as to the merits or fairness of this investment.
 

	

 
 	

(g)
 	

The Investor will acquire and hold the Shares and Warrants solely for his or her own account, as principal, for investment purposes only, with no present intention, agreement or arrangement to divide his or her participation with others or to resell, assign, transfer or otherwise dispose of all or any part of the Shares and Warrants subscribed for, and, further, that no other person or entity has any interest in the right to receive income in respect of the Investor’s interest in the Company.
 

	

 
 	

(h)
 	

In making his or her decision to purchase the Shares and Warrants herein subscribed for, the Investor has relied solely upon the information contained in the Memorandum, documents requested from the Company and the Investor’s own independent investigations, and has not relied upon any advertisement, article, notice, television/radio broadcast or other similar published communication or any seminar or meeting whose attendees are invited through any of the above-referenced published communications. Prior to the Investor’s initial communication with the Company in regards to the purchase of Investment Units the Investor did not learn of the opportunity to acquire Investment Units as a result of any article published or notification broadcast by any news media.
 

	

 
 	

(i)
 	

The Investor has been furnished with, and has reviewed, a copy of the Memorandum and any documents requested from the Company and has evaluated and considered the risks of a purchase of Investment Units (as set forth in the Memorandum under “RISK FACTORS,” and other sections) and is aware that there are substantial risks associated with an investment in the Investment Units.
 

	

 
 	

(j)
 	

The Investor has been given the opportunity:
 

	

 
 	

(i)
 	

to ask questions of the Company or the Placement Agent concerning the terms and conditions of the Offering and other matters pertaining to this investment and all such questions have been answered to the satisfaction of the Investor; and
 

	

 
 	

(ii)
 	

to obtain such additional information necessary to verify the accuracy of the information contained in the Memorandum or other provided materials, except such information that the Investor has requested in writing and that the Company or the Placement Agent has indicated it either does not possess and cannot acquire without unreasonable effort or expense or which is proprietary and confidential.
 

	

 
 	

(k)
 	

The Investor has not been furnished with any offering literature except the Memorandum or any requested information, and the Investor has not received any oral representations, warranties or other information from the Company, the Placement Agent or any of the Placement Agent’s Affiliates in connection with the Offering.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-4
 

	

 
 	

(l)
 	

The Investor fully understands and agrees that any certificate evidencing the Investment Units will bear the following legend:
 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER AND MAY NOT BE SOLD, EXCHANGED, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT (I) PURSUANT TO A REGISTRATION STATEMENT EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR (II) PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT.”

	

 
 	

(m)
 	

The Investor has no knowledge of any pending or threatened litigation the possible outcome of which may adversely affect the Investor’s responses and other representations contained in this Subscription Agreement or the Investor’s ability to perform his or her obligations in connection with his or her purchase of the Investment Units.
 

	

 
 	

(n)
 	

If the Investor’s Investment Units are held jointly either by a husband and wife or otherwise, or by more than one person as tenants in common, then each and every representation, warranty, covenant and agreement made in this Section 4 is made on behalf of each co-owner individually and is binding upon each such person and his heirs, executors, administrators, successors and assigns.
 

	

 
 	

(o)
 	

The Investor acknowledges, represents and agrees that no action has been or will be taken in any jurisdiction outside the United States by the Company that would permit an offering of the Shares, Warrant or Warrant Shares or possession or distribution of offering materials in connection with the issue of the Shares, Warrant or Warrant Shares in any jurisdiction outside the United States where legal action by the Company for that purpose is required. Each Investor outside the United States will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Shares, the Warrant or Warrant Shares or has in its possession or distributes any offering material, in all cases at its own expense.
 

	

 
 	

(p)
 	

The Investor hereby covenants with the Company that the Investor shall not make any sale of the Shares, Warrant or Warrant Shares without complying with the provisions of this Agreement and without causing the prospectus delivery requirement under the Securities Act to be satisfied (whether by delivery of the Prospectus or pursuant to and in compliance with an exemption from such requirement), and the Investor acknowledges that the certificates evidencing the Shares and Warrant Shares will be imprinted with a legend that prohibits their transfer except in accordance therewith.
 

	

 
 	

(q)
 	

If requested by the Company, the Investor will provide for presentation in the Registration Statement, the names of the persons with investment and voting authority over the Shares or Warrant Shares acquired hereunder and register thereon and such other information as is required by the SEC or reasonably requested by the Company in connection with the Registration Statement.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-5
 

	

 
 	

(r)
 	

The Investor further represents and warrants to, and covenants with, the Company that:
 

	

 
 	

(i)
 	

the Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement; and
 

	

 
 	

(ii)
 	

this Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except as the indemnification agreements of the Investors herein may be legally unenforceable.
 

	

 
 	

(s)
 	

Neither the Investor nor any person acting on the Investor’s behalf or at its direction has engaged in any purchase or sale of Shares (including without limitation any short sale, pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), during the ten (10) trading days immediately preceding the date of this Agreement. Subscriber agrees with the Company that the Company will be irreparably harmed if the Investor engages in short sales and similar hedging transactions. Therefore, Investor agrees that it will not directly or indirectly make or participate in any sale of the Shares, including “short sales” as defined in Rule 200
under Regulation SHO, whether or not exempt, until the earlier of (i) the effective date of the Registration Statement (defined below) or (ii) the 180th day after the Closing Date. Subscriber will not use any of the restricted Shares or the Warrant acquired pursuant to this Agreement, or the Warrant Shares acquired pursuant to the Warrant, to cover any short position in the Shares if doing so would be in violation of applicable securities laws and otherwise will comply with federal securities laws in the holding and sale of the Shares.
 

	

 
 	

(t)
 	

The Investor understands that nothing in the Memorandum, the Company’s filings with the SEC, this Agreement or any other materials presented to the Investor in connection with the purchase and sale of the Shares and the Warrants constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares and the Warrants.
 

	

5.
 	

Registration of the Shares; Compliance with the Securities Act.
 

	

 
 	

(a)
 	

The Company shall:
 

	

 
 	

(i)
 	

subject to receipt in a timely manner of necessary information from the Investors (after prompt request from the Company to the Investors to provide such information), including the information required to be provided pursuant to Section 4(q) of this Agreement, prepare and file with the SEC, within one hundred five (105) days after the Closing Date, a registration statement on Form S-3 (the “Registration Statement”) or such other form that is then available to the Company to enable the resale of the Shares and the Warrant Shares by the Investors from time to time in accordance with the plan of distribution to be described therein;
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-6
 

	

 
 	

(ii)
 	

subject to receipt of necessary information from the Investors (after prompt request from the Company to the Investors to provide such information), use its reasonable commercial efforts to cause the Registration Statement to become effective within one hundred eighty (180) days following the Closing Date;
 

	

 
 	

(iii)
 	

use its reasonable commercial efforts to prepare and file with the SEC such amendments and supplements to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement current, effective and free from any material misstatement or omission to state a material fact for a period (the “Registration Period”) not exceeding, with respect to each Investor’s Shares purchased hereunder and the Warrant Shares purchased under the Warrants, the earlier of: (i) the date that is two years after the Closing Date; or (ii) such time as all Shares purchased by such Investor in this Offering and Warrant Shares issuable pursuant to the
Warrants have been sold pursuant to a registration statement;
 

	

 
 	

(iv)
 	

furnish to the Investor with respect to the Shares and the Warrant Shares registered under the Registration Statement such number of copies of the Registration Statement and Prospectuses in conformity with the requirements of the Securities Act (which may be provided electronically) as the Investor may reasonably request in order to facilitate the public sale or other disposition of all or any of the Shares or Warrant Shares by the Investor; provided, however; that the obligation of the Company to deliver copies of Prospectuses to the Investor shall be subject to the receipt by the Company of reasonable assurances from the Investor that the Investor will comply with the applicable provisions of the Securities Act and of such other securities or blue sky laws as may be applicable in connection with any use of such Prospectuses;
 

	

 
 	

(v)
 	

bear all expenses in connection with the procedures in paragraph (i) through (iv) of this Section 5 (other than underwriting discounts or commissions, brokers’ fees and similar selling expenses, and any other fees or expenses incurred by the Investor, including attorney fees of the Investor) and the registration of the Shares and Warrant Shares pursuant to the Registration Statement; and
 

	

 
 	

(vi)
 	

advise the Investor, promptly (which advice may be provided electronically) after it shall receive notice or obtain knowledge of the issuance of any stop order by the SEC delaying or suspending the effectiveness of the Registration Statement or of the initiation or threat of any proceeding for that purpose, and it will promptly use its reasonable commercial efforts to prevent the issuance of any stop order or to obtain its withdrawal as soon as practicable if such stop order should be issued.
 

	

 
 	

(b)
 	

The Company understands that the Investor disclaims being an underwriter, but if the SEC deems the Investor to be an underwriter the Company shall not be relieved of any obligations it has hereunder; provided, however, that if the Company receives notification from the SEC that the Investor is deemed an underwriter, then the period by which the Company is obligated to submit an acceleration request to the SEC shall be extended to the earlier of (i) the 90th day after such SEC notification, or (ii) 120 days after the initial filing of the Registration Statement with the SEC. If required by the rules and regulations promulgated by the SEC, the Company may disclose the names of those Investors that may be deemed underwriters in the Registration Statement.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-7
 

	

6.
 	

Transfer of Shares After Registration; Suspension.
 

	

 
 	

(a)
 	

The Investor agrees that it will not effect any disposition of the Shares or its right to purchase the Shares or the Warrant Shares that would constitute a sale within the meaning of the Securities Act except as contemplated in the Registration Statement or as otherwise permitted by law, and in all cases in accordance with the procedures reasonably requested by the Company to ensure compliance with the securities laws, and that it will promptly notify the Company of any changes in the information set forth in the Registration Statement regarding the Investor.
 

	

 
 	

(b)
 	

Except in the event that paragraph (c) below applies, the Company shall: (i) if deemed necessary by the Company, prepare and file from time to time with the SEC a post-effective amendment to the Registration Statement or a supplement to the related Prospectus or a supplement or amendment to any document incorporated therein by reference or file any other required document so that such Registration Statement will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and so that, as thereafter delivered to purchasers of the Shares and Warrant Shares being sold thereunder, such Prospectus will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading, (ii) provide the Investor copies (which may be provided electronically) of any documents filed pursuant to Section 6(b)(i) as the Investor may reasonably request, and (iii) inform the Investor that the Company has complied with its obligations in Section 6(b)(i) (or that, if the Company has filed a post-effective amendment to the Registration Statement that has not yet been declared effective, the Company will notify the Investor to that effect, will use its reasonable commercial efforts to secure the effectiveness of such post-effective amendment as promptly as possible and will promptly notify the Investor when the amendment has become effective).
 

	

 
 	

(c)
 	

Subject to paragraph (d) below, in the event (i) of any request by the SEC or any other federal or state governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements to a Registration Statement or related Prospectus or for additional information, (ii) of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement or the initiation of any proceedings for that purpose, (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Shares or the Warrant Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, or (iv) of any event or circumstance which, upon the advice of
its counsel, necessitates the making of any changes in the Registration Statement or Prospectus, or any document incorporated or deemed to be incorporated therein by reference, so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or any omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the Prospectus, it will not contain any untrue statement of a material fact or any omission to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; then the Company shall deliver (which delivery may occur electronically) a certificate in writing to the Investor (the “Suspension Notice”) to the effect of the foregoing and, upon receipt of such
Suspension Notice, the Investor will refrain from selling any Shares and Warrant Shares pursuant to the Registration Statement (a “Suspension”) until the Investor’s receipt of copies (which may be provided electronically) of a supplemented or amended Prospectus prepared and filed by the Company, or until it is advised in writing by the Company that the current Prospectus may be used, and has received copies of any additional or supplemental filings that are incorporated or deemed incorporated by reference in any such Prospectus. In the event of any Suspension, the Company will use its reasonable commercial efforts to cause the use of the Prospectus so suspended to be resumed as soon as reasonably practicable within twenty (20) business days after the delivery of a Suspension Notice to the Investor. In addition to and without limiting any other remedies (including, without limitation, at law
or at equity) available to the Investor, the Investor shall be entitled to specific performance in the event that the Company fails to comply with the provisions of this Section 6(c).
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-8
 

	

 
 	

(d)
 	

Provided that a Suspension is not then in effect, the Investor may sell Shares under the Registration Statement, provided that it arranges for delivery of a current Prospectus to the transferee of such Shares and otherwise complies with applicable federal and state securities laws in connection with such sale.
 

	

 
 	

(e)
 	

In the event of a sale of Shares or Warrant Shares by the Investor pursuant to the Registration Statement, the Investor shall deliver to the Company’s transfer agent such documentation as reasonably required to effect such transfer.
 

	

7.
 	

Indemnification.
 

	

 
 	

(a)
 	

For the purpose of this Section 7:
 

	

 
 	

(i)
 	

the term “Selling Stockholder” means the Investor and any affiliate of such Investor;
 

	

 
 	

(ii)
 	

the term “Registration Statement” shall include the Prospectus in the form filed with the SEC pursuant to Rule 424(b) of the Securities Act or filed as part of the Registration Statement at the time of effectiveness if no Rule 424(b) filing is required, and any exhibit, supplement or amendment included in or relating to such Registration Statement or Prospectus; and
 

	

 
 	

(iii)
 	

the term “Untrue Statement” means any untrue statement or alleged untrue statement, or any omission or alleged omission to state in the Registration Statement a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-9
 

	

 
 	

(b)
 	

The Company agrees to indemnify and hold harmless each Selling Stockholder from and against any losses, claims, damages or liabilities to which such Selling Stockholder may become subject (under the Securities Act or otherwise) insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon: (i) any breach of the representations or warranties of the Company contained herein or failure to comply with the covenants and agreements of the Company contained herein, or (ii) any Untrue Statement, and the Company will reimburse such Selling Stockholder for any reasonable legal or other out-of-pocket expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim, or preparing to defend any such action, proceeding or claim, provided,
however, that the Company shall not be liable in any such case to the extent that such loss, claim, damage or liability arises out of, or is based upon, an Untrue Statement made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Selling Stockholder specifically for use in preparation of the Registration Statement, as amended or supplemented from time to time (including, without limitation, information set forth in this Subscription Agreement), or the failure of such Selling Stockholder to comply with its covenants and agreements contained in this Agreement. The Company shall reimburse each Selling Stockholder for the indemnifiable amounts provided for herein on demand as such expenses are incurred.
 

	

 
 	

(c)
 	

The Investor agrees to indemnify and hold harmless the Company (and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act, each officer of the Company who signs the Registration Statement and each director of the Company) from and against any losses, claims, damages or liabilities to which the Company (or any such officer, director or controlling person) may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon (i) any failure to comply with the covenants and agreements contained in this Agreement, or (ii) any Untrue Statement if such Untrue Statement was made in reliance upon and in conformity with written information furnished by or on behalf of the Investor specifically
for use in preparation of the Registration Statement, as amended or supplemented from time to time (including, without limitation, information set forth in this Subscription Agreement), and the Investor will reimburse the Company (or such officer, director or controlling person), as the case may be, for any legal or other out-of-pocket expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim. The Investor shall reimburse the Company or such officer, director or controlling person, as the case may be, for the indemnifiable amounts provided for herein on demand as such expenses are incurred. Notwithstanding the foregoing, the Investor’s aggregate obligation to indemnify the Company and such officers, directors and controlling persons shall be limited to the net amount received by the Investor from the sale of the Shares less the amount of any other claims, damages or liabilities paid by the Investor in connection with such
Investor’s sale of the Shares.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-10
 

	

 
 	

(d)
 	

Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in respect of which indemnity is to be sought against an indemnifying person pursuant to this Section 7, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such action, but the omission to so notify the indemnifying person will not relieve it from any liability which it may have to any indemnified person under this Section 7 (except to the extent that such omission materially and adversely affects the indemnifying person’s ability to defend such action) or from any liability otherwise than under this Section 7. Subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person, the indemnifying person shall be entitled to participate
therein, and, to the extent that it shall elect by written notice delivered to the indemnified person promptly after receiving the aforesaid notice from such indemnified person, shall be entitled to assume the defense thereof, with counsel reasonably satisfactory to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof, such indemnifying person shall not be liable to such indemnified person for any legal expenses subsequently incurred by such indemnified person in connection with the defense thereof, provided, however, that if there exists or shall exist a conflict of interest that would make it inappropriate, in the opinion of counsel to the indemnified person, for the same counsel to represent both the indemnified person and such indemnifying person or any affiliate or associate thereof, the indemnified person shall be entitled to retain its own counsel at the expense of such indemnifying person;
provided, however, that no indemnifying person shall be responsible for the fees and expenses of more than one separate counsel (together with appropriate local counsel) for all indemnified parties. In no event shall any indemnifying person be liable in respect of any amounts paid in settlement of any action unless the indemnifying person shall have approved the terms of such settlement; provided that such consent shall not be unreasonably withheld or delayed. No indemnifying person shall, without the prior written consent of the indemnified person, effect any settlement of any pending or threatened proceeding in respect of which any indemnified person is or could have been a party and indemnification could have been sought hereunder by such indemnified person, unless such settlement includes an unconditional release of such indemnified person from all liability on claims that are the subject matter of such proceeding.
 

	

 
 	

(e)
 	

If the indemnification provided for in this Section 7 is unavailable to or insufficient to hold harmless an indemnified person under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions or proceedings in respect thereof) referred to therein, then each indemnifying person shall contribute to the amount paid or payable by such indemnified person as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the Company on the one hand and the Investor, as well as any other Selling Stockholders under such Registration Statement on the other in connection with the statements or omissions or other matters which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any
other relevant equitable considerations. The relative fault shall be determined by reference to, among other things, in the case of an Untrue Statement, whether the Untrue Statement relates to information supplied by the Company on the one hand or an Investor or other Selling Stockholder on the other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such Untrue Statement. The Company and the Investor agree that it would not be just and equitable if contribution pursuant to this subsection (e) were determined by pro rata allocation (even if the Investor and other Selling Stockholders were treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations referred to above in this subsection (e). The amount paid or payable by an indemnified person as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in
this subsection (e) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified person in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (e), the Investor shall not be required to contribute any amount in excess of the amount by which the net amount received by the Investor from the sale of the Shares to which such loss relates exceeds the amount of any damages that such Subscriber has otherwise been required to pay by reason of such Untrue Statement. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Investor’s obligations in this subsection to contribute shall be in proportion to its Investor sale of Shares and Warrant Shares to which such loss relates and shall not be joint with any other Selling
Stockholders.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-11
 

	

 
 	

(f)
 	

The parties to this Agreement hereby acknowledge that they are sophisticated business persons who were represented by counsel during the negotiations regarding the provisions hereof including, without limitation, the provisions of this Section 7, and are fully informed regarding said provisions. They further acknowledge that the provisions of this Section 7 fairly allocate the risks in light of the ability of the parties to investigate the Company and its business in order to assure that adequate disclosure is made in the Registration Statement as required by the Securities Act and the Exchange Act. The parties are advised that federal or state public policy as interpreted by the courts in certain jurisdictions may be contrary to certain of the provisions of this Section 7, and the parties hereto hereby expressly waive and relinquish any right or
ability to assert such public policy as a defense to a claim under this Section 7 and further agree not to attempt to assert any such defense.
 

	

8.
 	

Termination of Conditions and Obligations. The conditions precedent imposed by Section 6 upon the transferability of the Shares and Warrant Shares shall cease and terminate as to any particular number of the Shares when such Shares shall have been effectively registered under the Securities Act and sold or otherwise disposed of in accordance with the intended method of disposition set forth in the Registration Statement covering such Shares or at such time as an opinion of counsel reasonably satisfactory to the Company shall have been rendered to the effect that such conditions are not necessary in order to comply with the Securities Act.
 

	

9.
 	

Legend; Restrictions on Transfer. The certificate or certificates for the Shares and the Warrants and any securities issued in respect of or exchange for the Shares or Warrants) shall be subject to a legend or legends restricting transfer under the Securities Act and referring to restrictions on transfer herein, such legend to be substantially as follows (and any additional legend required under the Securities Act and otherwise):
 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL, IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-12
 

The Company and the Investor acknowledge and agree that the Investor may, as permitted by law, from time to time pledge pursuant to a bona fide margin agreement or grant a security interest in some or all of the Shares and Warrants and, if required under the terms of such arrangement, Subscriber may, as permitted by law, transfer pledged or secured Shares and Warrants to the pledgees or secured parties. So long as Subscriber is not an affiliate of the Company, such a pledge or transfer in compliance with all applicable federal and state securities laws would not be subject to approval or consent of the Company, provided that, upon the request of the Company, a legal opinion of legal counsel to the pledgee, secured party or pledgor shall be obtained. At the Investor’s sole expense, so long as the Shares and Warrants are subject to the legend required by this Section 9, the
Company will use its reasonable commercial efforts to execute and deliver such reasonable documentation as a pledgee or secured party of Shares and Warrants may reasonably request in connection with a pledge or transfer of the Shares and Warrants including such amendments or supplements to the Registration Statement and Prospectus as may be reasonably required. The foregoing does not affect Subscriber’s obligations pursuant to Section 6.

	

10.
 	

Indemnification of the Company and Affiliates. Notwithstanding anything else contained herein to the contrary, the Investor hereby agrees to indemnify the Company, the Placement Agent and their respective employees, agents, Affiliates, officers, directors, general partners, and the employees of each of them and to hold each of them harmless from and against any and all liability, damage, cost or expense (including reasonable attorney’s fees and costs of suit) incurred on account of or arising out of:
 

	

 
 	

(a)
 	

any inaccuracy or omission in the Investor’s declarations, representations and warranties as set forth herein;
 

	

 
 	

(b)
 	

the disposition of the Investor’s Shares and Warrants in a manner contrary to his declarations, representations and warranties as made herein; and
 

	

 
 	

(c)
 	

any action, suit or proceeding based upon: (i) the claim that said declarations, representations, or warranties were inaccurate or misleading or otherwise cause for obtaining damages or redress from the Company, the Placement Agent or their respective Affiliates, officers, employees or agents; or (ii) the disposition of any of the Shares and Warrants or any part thereof.
 

	

11.
 	

Modification. The provisions of this Subscription Agreement shall not be modified, discharged or terminated, except by an instrument in writing signed by the party against whom any waiver, change, discharge or termination is sought.
 

	

12.
 	

Notices. Any notice, demand or other communication that any party hereto may be required, or may elect, to give to anyone interested hereunder shall be sufficiently given if: (a) sent by telefax, facsimile or electronic mail if sent during normal business hours, and, if not on the next business day, (b) deposited, postage prepaid, in a United States mail letter box, registered or certified mail, return receipt requested, addressed to such address as may be given herein; or (c) delivered personally at such address.
 

	

13.
 	

Counterparts. This Subscription Agreement may be executed through the use of separate signature pages or in any number of counterparts (including facsimile counterparts), and each of such counterparts shall, for all purposes, constitute one agreement binding on all the parties, notwithstanding that all parties are not signatories to the same counterpart.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-13
 

	

14.
 	

Binding Effect. Except as otherwise provided herein, this Subscription Agreement shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives and assigns. If the Investor is more than one person, the obligation of the Investor shall be joint and several, and the agreements, representations, warranties and acknowledgments herein contained shall be deemed to be made by and be binding upon each such person and his heirs, executors, administrators and successors.
 

	

15.
 	

Entire Agreement. This Subscription Agreement contains the entire agreement of the parties, and there are no representations, covenants or other agreements except as stated or referred to herein (or therein).
 

	

16.
 	

Assignability. This Subscription Agreement is not transferable or assignable by the Investor except as expressly provided herein.
 

	

17.
 	

Applicable Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to conflict of law principles..
 

	

18.
 	

Representations Shall Survive Closing. All representations and warranties set forth in Paragraphs 2, 3, 4, 19, and 20 and understandings set forth in Paragraphs 7 and 10 or in any other written statement or document delivered by the Investor in connection with the transactions contemplated hereby will be true, correct and complete in all respects on and as of the date of Closing as if made on and as of such date and shall survive the Closing and the delivery by to the Investor of the Shares and Warrants.
 

	

19.
 	

Investor Experience. The Investor acknowledges, represents and warrants to the Company and the Placement Agent that either: (i) the Investor alone has such knowledge and experience in financial and business matters as to be capable of making an informed decision regarding an investment in the Investment Units; or (ii) the Investor is relying on the advice of a Purchaser Representative, not affiliated with the Company, the Placement Agent or their respective Affiliates, who has such knowledge and experience in financial and business matters as to be able to advise the Investor of the merits and risks of the investment with respect to the Investor’s individual financial circumstances and who has submitted a signed Purchaser Representative Letter and Questionnaire (in a form satisfactory to the Placement
Agent) to the Company.
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-14
 

  	
        THE
          INVESTOR IS RELYING UPON A PURCHASER REPRESENTATIVE

      
	
        

          (CHECK ONE):

      	
        YES

      	
         

      	
        NO

      	
         

      

 

 

  	

 
 
	

(Name of Purchaser Representative, if any)
  
  
 
	

(Occupation)
  
  
 
	

(Relationship to Subscriber)
  
  
 

 

	

Beijing Med-Pharm Corporation
 	

Subscription Agreement
 Page B-15
 

	

20.
 	

Accredited Investor Representation. The Investor understands that the Investment Units may only be offered and sold to Investors who are “Accredited Investors” and that the Investor’s representation to the Placement Agent in this regard are material inducements to the Placement Agent’s acceptance of this Subscription. IN ACCORDANCE WITH THE FOREGOING, PLEASE INDICATE WHICH ONE OF THE FOLLOWING CATEGORIES YOU BELIEVE APPROPRIATELY DESCRIBES THE INVESTOR’S STATUS AS AN “ACCREDITED INVESTOR” BY INITIALING THE APPROPRIATE AFFIRMATIVE RESPONSE.
 

 

  	
         
 	
        INITIAL
          IF

          REPRESENTATION

          IS CORRECT

      	
         

      	

        ACCREDITED
          INVESTOR CATEGORY

      

 

  	
         

      	
        (A)

      	
         

      	
         

      	
         

      	

The Investor is a director or executive officer of the Placement Agent of the Company.
 
	
         
 	
         
 	
         
 	
         
 	
         
 	
         
 
	

 
 	

(B)
 	

 
 	

 
 	

 
 	

The Investor is a corporation, partnership or business trust with total assets in excess of $5,000,000.00.
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	

(C)
 	

 
 	

 
 	

 
 	

The Investor is an individual whose current net worth, or joint net worth with that of the spouse of the Investor, exceeds $1,000,000.00.
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	

(D)
 	

 
 	

 
 	

 
 	

The Investor is an individual who had individual income in excess of $200,000.00 in 2004 and 2005 or joint income with the Investor’s spouse in excess of $300,000.00 in each of those years and who reasonably expects the same income level in 2006.
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	

(E)
 	

 
 	

 
 	

 
 	

The Investor is a trust with total assets in excess of $5,000,000.00, not formed for the specific purpose of purchasing Investment Units, whose purchase is directed by a sophisticated person.
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	

(F)
 	

 
 	

 
 	

 
 	

The Investor is an employee benefit plan that meets the criteria set forth in (vi) above.
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	

(G)
 	

 
 	

 
 	

 
 	

The Investor is an entity in which all of the equity owners are accredited investors.
 

 

	

        Beijing
          Med-Pharm Corporation

      	

        Subscription
          Agreement

          Page B-16

      

 

	

21.
 	

Registration of Share and Share Ownership (check one):
 

NOTE: Subscribers should seek the advice of their attorneys in deciding in which of the below forms they should take ownership of the Shares and Warrants, since different forms of ownership can have varying gift tax, estate tax, income tax and other consequences, depending on the state of the Investor’s domicile and other particular personal circumstances of the Investor.

 

  	
         

      	
        INITIAL
          FOR

          APPROPRIATE

          REGISTRATION

          INSTRUCTIONS

      	
         

      	
        FORM
          OF REGISTRATION AND OWNERSHIP

      

 

  	
         

      	
         

      	
         

      	
        Individual ownership (one signature is required)
 
	

 
 	

 
 	

 
 	

 
 
	

 
 	

 
 	

 
 	

Husband and Wife or other Joint Tenants with right of survivorship (both parties must sign)
 
	

 
 	

 
 	

 
 	

 
 
	

 
 	

 
 	

 
 	

Tenants in Common with no right of survivorship (all parties must sign)
 
	

 
 	

 
 	

 
 	

 
 
	

 
 	

 
 	

 
 	

Partnership (include name of the Partnership, date the Partnership was formed, and copy of the Partnership Agreement or other authorization other authorization with respect to the purchase of Investment Units)
 
	

 
 	

 
 	

 
 	

 
 
	

 
 	

 
 	

 
 	

Corporation (include name of Corporation and copy of resolution or other authorization with respect to the purchase of Investment Units)
 
	

 
 	

 
 	

 
 	

 
 
	

 
 	

 
 	

 
 	

Limited Liability Company (including name of the Limited Liability Company, date the Limited Liability Company was formed, a copy of the Limited Liability Company Operating Agreement or other authorization with respect to the purchase of Investment Units
 
	

 
 	

 
 	

 
 	

 
 
	

 
 	

 
 	

 
 	

Trust (include name of Trust, date Trust was formed, and copy of the Trust Agreement or other authorization other authorization with respect to the purchase of Investment Units)
 

PLEASE PRINT HERE THE EXACT NAME OR NAMES (REGISTRATION) SUBSCRIBER DESIRES

 

  	
        ON
          ITS ACCOUNT:

      	
         

      	
         

      	 
	
         

      	
         

      	
         

      	 
	
         

      	
         

      	
        Rest
          of page intentionally left blank.

      	 

 

	

        Beijing
          Med-Pharm Corporation

      	

        Subscription
          Agreement

          Page B-17

      

 

	

22.
 	

Amount of Subscription:
 

 

  	
         

      	
        Number of Investment Units
 	
         

      	
         
 	
         

      	
         
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	

Subscription price per Investment Unit
 	

 
 	

        x

      	

 
 	

$100,000
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

 
 
	

 
 	
        Total
          subscription price payable to the Company

      	

 
 	

 
 	

 
 	

$
 
	

 
 	

 
 	

 
 	

 
 	

 
 	

        ________________

      

 

  	
         
 	
         
 	
         
 
	
         
 	
         
 	
         
 
	
         
 	
        Signatures appear on next page.
 	
         
 

 

	

        Beijing
          Med-Pharm Corporation

      	

        Subscription
          Agreement

          Page B-18

      

IN WITNESS WHEREOF, the undersigned Subscriber has completed and executed this Subscription Agreement to evidence Subscriber’s subscription for Investment Units of Common Stock and Warrants of Beijing Med-Pharm Corporation this _________ day of December, 2006. 

If the Subscription Agreement is accepted by one or more individual subscribers, use the following signature lines and format:

 

  	
        SUBSCRIBER:

      	
         

      	
         

      	
        SUBSCRIBER:

      	
         

      
	 	
        

      	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
        NAME:

      	
         

      	
         

      	
         

      	
        NAME:

      	
         

      
	 	 	
        

      	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
        ADDRESS:

      	
         

      	
         

      	
         

      	
        ADDRESS:

      	
         

      
	 	 	
        

      	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	 	
        

      	 	
        

      
	 	 	 	
	
         

      	
        

      	
         

      	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
        SOCIAL
          SECURITY NO. OR
          TAX ID NO.:

      	
         

      	
         

      	
        SOCIAL
          SECURITY NO. OR
          TAX ID NO.:

      	
         

      
	 	 	
        

      	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
        E-MAIL
          ADDRESS:

      	
         

      	
         

      	
        E-MAIL
          ADDRESS:

      	
         

      
	 	 	
        

      	 	 	
        

      
												

            

If the Subscription Agreement is executed by a corporation or other entity please use the following signature lines and format:

 

  	
        ATTEST/WITNESS:

      	
         

      	
        SUBSCRIBER:

      
	
         

      	
         

      	
         

      	
         

      
	
        BY:

      	
         

      	
         

      	
         

      
	 	
        

      	 	
        

      
	
         

      	
         

      	
         

      	
        [NAME
          OF ENTITY]

      
	
        NAME:

      	
         

      	
         

      	
         

      
	 	
        

      	 	 	 
	
         

      	
         

      	
         

      	
         

      	
         

      
	
        TITLE:

      	
         

      	
         

      	
        BY:

      	
         

      
	 	
        

      	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
        NAME:

      	
         

      
	 	 	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
        TITLE:

      	
         

      
	 	 	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
        ADDRESS
          OR PRINCIPAL PLACE OF
          BUSINESS:

      
	
         

      	
         

      	
         

      	
         

      
	 	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
        SOCIAL
          SECURITY NO. OR TAX
          ID NO.

      	
         

      
	 	 	 	 	
        

      
	
         

      	
         

      	
         

      	
         

      	
         

      
	
         

      	
         

      	
         

      	
        E-MAIL
          ADDRESS:

      	
         

      
	 	 	 	 	
        

      
							

            

 

	

        Beijing
          Med-Pharm Corporation

      	

        Subscription
          Agreement

          Page B-19

      

The Undersigned, as an authorized officer of Beijing Med-Pharm Corporation (the “Company”), has accepted this Subscription Agreement on behalf of the Company as of the ________ day of December, 2006.

 

  	
         

      	
         

      	
        BEIJING
          MED-PHARM CORPORATION

      
	 	 	 	 
	
        
        

      	
         

      	
        BY: 

      	
        
        

      
	 	 	 	
        

      
	
         

      	
         

      	
        NAME:

      	
         

      
	 	 	 	
        

      
	
         

      	
         

      	
        TITLE:

      	
         

      
	 	 	 	
        

      

 

  	
        ACCEPTED:

      	
         

      	
         

      
	
         

      	
         

      	
         

      
	
        PHILADELPHIA
          BROKERAGE CORPORATION, AS
          PLACEMENT AGENT

      	
         

      	
         

      
	 	 	 	 	 
	
        BY: 

      	
        
        

      	
         

      	
         

      	
         

      
	 	
        

      	 	 	 
	
        NAME:

      	
         

      	
         

      	
         

      	
         

      
	 	
        

      	 	 	 
	
        TITLE:

      	
         

      	
         

      	
         

      	
         

      
	 	
        

      	 	 	 

 

	

        Beijing
          Med-Pharm Corporation

      	

        Subscription
          Agreement

          Page B-20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]